Boulder pharmaceutical agency Array BioPharma, Inc. posted losses of greater than $147.three million for the complete 2018 fiscal yr, which ended June 30. That loss is up from $116.eight million in 2017.
The corporate’s monetary outcomes have been introduced Tuesday, lower than two months after the U.S. Meals and Drug Administration permitted the mixture of Array medication Braftovi and Mektovi for the remedy of a kind of pores and skin most cancers known as BRAF-mutant melanoma. The mix hit the market in early July.
Array’s losses for the fiscal yr have been largely pushed by analysis and growth prices related to commercializing Braftovi and Mektovi, firm executives stated on a convention name with traders Tuesday.
“As we’re solely six weeks into launch, it’s too early to share particular gross sales estimates or prescription tendencies, however we’re excited to report that early demand for melanoma prescribers for our mixture has been robust,” Array CEO Ron Squarer stated.
The corporate, which this week named a brand new chairman for its board of administrators, additionally has a colorectal most cancers drug mixture within the growth pipeline.
Learn the complete story at dailycamera.com.